Compare Arko Corp. (ARKO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arko Corp. vs Recursion Pharmaceuticals Inc — how do they compare? Arko Corp. trades at $4.33 (market cap $527.27M), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 3.4× Arko Corp.'s market cap, and Arko Corp. pays a 2.55% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ARKO | RXRX | |
|---|---|---|
Market Cap | $527.27M | $1.78B |
Sector | Consumer Cyclical | Health |
52-Week High | $8.64 | $6.79 |
52-Week Low | $3.82 | $2.84 |
Enterprise Value | $2.71B | $1.30B |
Dividend Yield | 2.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKO Corp. (NASDAQ: ARKO) trades at $5.66, down 22.36% following weak Q2 2026 earnings that missed expectations. The stock shows bearish technical signals with oversold RSI readings near support at $5. Despite revenue declining to $7.64B in 2025, the company maintains positive cash flow and recently paid a $0.03 dividend. Analyst consensus remains cautious with 100% hold ratings amid concerns about consumer spending pressures.
The outlook remains challenging with declining revenues and thin profit margins (0.38% net margin), though management maintains 2026 EBITDA guidance. Key risks include competitive pressure in convenience retail and sensitivity to fuel price volatility. The current valuation at 0.08 P/S ratio may attract value investors if operational improvements materialize.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arko Corp.
ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Read more on ARKO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
